C12N 2795/10034
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2795/10034 (Use of virus or viral component as vaccine) appears on 1 US grants and 4 published applications in this corpus.
Search patents in C12N- Granted patents
- 1
- Published applications
- 4
- Assignees
- 5
- Inventors
- 17
- Latest grant
- 13 May 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2021 | 0 | 1 |
| 2022 | 0 | 0 |
| 2023 | 0 | 1 |
| 2024 | 0 | 0 |
| 2025 | 1 | 1 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Modular bacteriophage t4 nanoparticle platform enables rapid design of dual covid-19-flu mucosal vaccines26 Mar 2026US 2026/0083835 A1The Catholic University of America
- Bacteriophage7 Aug 2025US 2025/0249085 A1Glaxosmithkline Biologicals SA
- Coronavirus vaccines comprising a tlr9 agonist13 Apr 2023US 2023/0110516 A1Dynavax Technologies Corporation
- Immunogenic composition against severe acute respiratory syndrome coronavirus 2 (sars-cov-2)7 Oct 2021US 2021/0308257 A1Dynavax Technologies Corporation
Most cited
By later US patents
No patent in this class has been cited by a later US patent yet.